Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution.
about
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromesNeuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive ReviewUpdate on surgical treatment of pancreatic neuroendocrine neoplasmsSurgical management of pancreatico-duodenal tumors in multiple endocrine neoplasia syndrome type 1DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumorsStreptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment StratificationSystematic review and meta-analysis on laparoscopic pancreatic resections for neuroendocrine neoplasms (PNENs).Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.Surgical resection improves the outcome of the patients with neuroendocrine tumor liver metastases: large data from AsiaComparison of relapse-free survival in gastric neuroendocrine carcinoma (WHO grade 3) and gastric carcinoma.Pancreatic neuroendocrine tumors: the basics, the gray zone, and the target.Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in ChinaDeveloping a multivariable prognostic model for pancreatic endocrine tumors using the clinical data warehouse resources of a single institution.ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group.Clinicopathological features of small nonfunctioning pancreatic neuroendocrine tumorsTumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors.Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resectionSmall cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumorsGuidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)Hyaline globules in neuroendocrine and solid-pseudopapillary neoplasms of the pancreas: a clue to the diagnosis.Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours.Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors.Prognostic relevance of survivin in pancreatic endocrine tumorsLymph nodes and survival in pancreatic neuroendocrine tumors.Cytoplasmic Clusterin expression correlates with pancreatic neuroendocrine tumor size and pathological stage.Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems.Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfallsRisk factors for aggressive nonfunctional pancreatic neuroendocrine tumors and the role of endoscopic ultrasound guided fine-needle aspirationThe importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index.A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasmsDiffering Clinical Courses and Prognoses in Patients With Gastric Neuroendocrine Tumors Based on the 2010-WHO Classification Scheme.Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advancesDifferences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States: A Multicenter StudyGrading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors.
P2860
Q24603675-ECAB2891-589C-434C-98E0-D2C17A96CB0FQ26768483-66D11959-634A-4083-A807-961A14ABE69EQ26864361-36C5E4E6-7F29-4502-890A-251283934112Q26998951-B374493A-62E0-413B-95C7-81136546F853Q28303693-FBCCDEAB-23B8-4F1D-8AED-741CEC6627F2Q28551275-0CC404D5-A3B1-4C0C-8AD3-A0DC2C812F2FQ30244079-0F1E1221-E1FD-4EDA-BF91-BF325817CEB7Q30249051-56F0A875-1820-40E7-8136-EEB0F0F33DBAQ30884528-A5B1460C-A768-422F-8765-E1F1F0F749DAQ33632569-7F89853C-85A9-4A89-BA4B-E4CA3E05B838Q33672117-FCC9552B-75B5-48BB-9BCA-486264F7BE11Q33684746-2B61BFE1-6E4B-46F6-8778-A41892195D6DQ33892438-FBEA4493-C7DE-4BCA-9DB0-541E627379BAQ34248487-7339E10C-99C1-4754-8C7F-CC56CFBA0003Q34301030-C7407F7B-7120-4BBF-BEFE-3C3D4C4D79F9Q34446086-FB444C70-7549-4364-B2F4-FAC9E5BA5D3DQ34750730-FFB2F15E-1F6D-4FA4-804C-0E57BDD69438Q35034000-C924A5F9-A05E-465A-B66B-85C74814FEDBQ35065094-C0AF510D-1032-4D77-B974-D7704B4CE0D0Q35681234-0D9C480B-8E05-4028-8E43-93CD5232C3FFQ35760798-311A64F7-FACD-41E9-A47D-90F20D06A993Q35768274-1C950DBB-A20D-406F-A1F6-3E7B7B417A13Q35783628-8A3A9542-79BE-4610-95F0-80D2B85FBBA8Q35895493-764B21C2-AD95-4B0F-AAAB-C660F6EEB839Q35947272-46D0D148-F4FF-4384-A235-BA374A718364Q36250472-514E7C88-B960-456C-AE28-3051F60600E6Q36280303-1FEE8BE0-C4EE-4593-BA3D-946E36353B8AQ36344419-060BED0E-32EA-4A22-A82B-2BCFE372CD9CQ36359089-596144E3-35D1-4DCD-8696-2AC894F7456BQ36582343-67869205-A20B-4E07-894B-4D53D69946A0Q36629127-1325D293-D5AF-41DC-A244-B16FA6E7C1EAQ36681892-97F13ED3-9056-45CF-B171-ADEBD8429138Q36857533-A5E405C5-4D43-4D21-A63E-8198E7519F03Q37026099-7D65C753-D76A-4E5A-997B-B5EA614C8682Q37056120-4B191DF1-601F-446F-A9B0-347736F643DCQ37085554-33DCC84A-E921-4315-88E1-BC48F3E97DBCQ37125550-DE741DD3-2AA8-4E6D-98DF-F2FA2540CA68Q37206218-80510B2F-F005-439D-A924-2D773CF90671Q37478823-05C3D060-75AE-411A-8D26-516CEB5AEB61Q37531108-2E3472EA-4425-4FCF-8A66-19EAEE8765B1
P2860
Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Prognostic factors and surviva ...... eated at a single institution.
@en
Prognostic factors and surviva ...... eated at a single institution.
@nl
type
label
Prognostic factors and surviva ...... eated at a single institution.
@en
Prognostic factors and surviva ...... eated at a single institution.
@nl
prefLabel
Prognostic factors and surviva ...... eated at a single institution.
@en
Prognostic factors and surviva ...... eated at a single institution.
@nl
P2093
P1476
Prognostic factors and surviva ...... eated at a single institution.
@en
P2093
Barbro Eriksson
Britt Skogseid
Kjell Oberg
Kristina Dunder
Sara Ekeblad
P304
P356
10.1158/1078-0432.CCR-08-0734
P407
P577
2008-12-01T00:00:00Z